Tags

Type your tag names separated by a space and hit enter

A double blind, randomized, placebo controlled study to evaluate the efficacy of erythromycin in patients with knee effusion due to osteoarthritis.
Int J Rheum Dis. 2009 Apr; 12(1):44-51.IJ

Abstract

OBJECTIVE

The efficacy of erythromycin in treatment of knee effusion due to osteoarthritis was evaluated.

METHOD

We assessed efficacy and safety of erythromycin during 16 weeks in patients enrolled in a randomized double-blind study. One hundred and eight patients with knee effusion due to osteoarthritis (OA) received 12-week courses of erythromycin or placebo allocated randomly, and were followed for 4 months. Acetaminophen 650 mg/day was used in both groups, while they received no other anti-inflammatory drugs (such as corticosteroid or nonsteroidal anti-inflammatory drugs) during the course of the study. Our patients were divided in two groups, erythromycin in doses of 200 mg four times per day was given to the first group (51 patients) over the first 3 months of the study and in the second group we used placebo with the same dosage and schedule (53 patients). Outcomes improvement for the erythromycin-treated group was assessed by a significantly higher mean score from baseline to the end of the trial, compared with placebo group. Patients were examined monthly during the treatment period. Measurement values included recording of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) questionnaire subscales (pain, stiffness and function), range of motion and knee circumference.

RESULTS

Erythromycin produced a higher response rate than placebo in treatment of knee effusion due to OA. Significant reduction in knee circumference (P < 0.0005) and pain (P < 0.001) with functional improvement (P < 0.0005) were seen. At the first month after treatment, 11.8% (6 patients) in erythromycin and 9.4% (5 patients) in placebo groups had 50% pain reduction, which was not significant (P = 0.75). At the fourth month, 50% reduction of pain was seen in 45.1% (23 patients) of the erythromycin and 11.3% (6 patients) of the placebo group. This was statistically significant (P < 0.0005). Erythromycin treatment was well tolerated and mild adverse events caused no discontinuation during the study.

CONCLUSION

This is a placebo-controlled study of macrolid efficacy on knee effusion due to OA in a short period. Results of this research showed the better efficacy of erythromycin in controlling effusion and pain with functional improvement in patients with knee effusion due to OA.

Authors+Show Affiliations

Tabriz University (Medical Sciences), Tabriz, Iran. shahramsd2005@yahoo.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

20374316

Citation

Sadreddini, Shahram, et al. "A Double Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy of Erythromycin in Patients With Knee Effusion Due to Osteoarthritis." International Journal of Rheumatic Diseases, vol. 12, no. 1, 2009, pp. 44-51.
Sadreddini S, Noshad H, Molaeefard M, et al. A double blind, randomized, placebo controlled study to evaluate the efficacy of erythromycin in patients with knee effusion due to osteoarthritis. Int J Rheum Dis. 2009;12(1):44-51.
Sadreddini, S., Noshad, H., Molaeefard, M., Moloudi, R., Ardalan, M. R., & Ghojazadeh, M. (2009). A double blind, randomized, placebo controlled study to evaluate the efficacy of erythromycin in patients with knee effusion due to osteoarthritis. International Journal of Rheumatic Diseases, 12(1), 44-51. https://doi.org/10.1111/j.1756-185X.2009.01379.x
Sadreddini S, et al. A Double Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy of Erythromycin in Patients With Knee Effusion Due to Osteoarthritis. Int J Rheum Dis. 2009;12(1):44-51. PubMed PMID: 20374316.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A double blind, randomized, placebo controlled study to evaluate the efficacy of erythromycin in patients with knee effusion due to osteoarthritis. AU - Sadreddini,Shahram, AU - Noshad,Hamid, AU - Molaeefard,Mahshid, AU - Moloudi,Ramona, AU - Ardalan,Mohamad-Reza, AU - Ghojazadeh,Morteza, PY - 2010/4/9/entrez PY - 2010/4/9/pubmed PY - 2010/6/25/medline SP - 44 EP - 51 JF - International journal of rheumatic diseases JO - Int J Rheum Dis VL - 12 IS - 1 N2 - OBJECTIVE: The efficacy of erythromycin in treatment of knee effusion due to osteoarthritis was evaluated. METHOD: We assessed efficacy and safety of erythromycin during 16 weeks in patients enrolled in a randomized double-blind study. One hundred and eight patients with knee effusion due to osteoarthritis (OA) received 12-week courses of erythromycin or placebo allocated randomly, and were followed for 4 months. Acetaminophen 650 mg/day was used in both groups, while they received no other anti-inflammatory drugs (such as corticosteroid or nonsteroidal anti-inflammatory drugs) during the course of the study. Our patients were divided in two groups, erythromycin in doses of 200 mg four times per day was given to the first group (51 patients) over the first 3 months of the study and in the second group we used placebo with the same dosage and schedule (53 patients). Outcomes improvement for the erythromycin-treated group was assessed by a significantly higher mean score from baseline to the end of the trial, compared with placebo group. Patients were examined monthly during the treatment period. Measurement values included recording of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) questionnaire subscales (pain, stiffness and function), range of motion and knee circumference. RESULTS: Erythromycin produced a higher response rate than placebo in treatment of knee effusion due to OA. Significant reduction in knee circumference (P < 0.0005) and pain (P < 0.001) with functional improvement (P < 0.0005) were seen. At the first month after treatment, 11.8% (6 patients) in erythromycin and 9.4% (5 patients) in placebo groups had 50% pain reduction, which was not significant (P = 0.75). At the fourth month, 50% reduction of pain was seen in 45.1% (23 patients) of the erythromycin and 11.3% (6 patients) of the placebo group. This was statistically significant (P < 0.0005). Erythromycin treatment was well tolerated and mild adverse events caused no discontinuation during the study. CONCLUSION: This is a placebo-controlled study of macrolid efficacy on knee effusion due to OA in a short period. Results of this research showed the better efficacy of erythromycin in controlling effusion and pain with functional improvement in patients with knee effusion due to OA. SN - 1756-185X UR - https://www.unboundmedicine.com/medline/citation/20374316/A_double_blind_randomized_placebo_controlled_study_to_evaluate_the_efficacy_of_erythromycin_in_patients_with_knee_effusion_due_to_osteoarthritis_ DB - PRIME DP - Unbound Medicine ER -